KORU Medical (KRMD) grants RSUs, PSUs and options to President

Rhea-AI Filing Summary

KORU Medical Systems reported that its President and Chief Commercial Officer, Adam R. Kalbermatten, received new equity awards as part of his compensation. He was granted 45,098 restricted stock units and 45,098 performance stock units, each representing the right to receive one share of common stock upon vesting.

The restricted stock units vest in equal annual installments beginning on March 17, 2027. The performance stock units vest based on achievement of performance conditions measured as of December 31, 2028, with potential payout ranging from 0% to 150% of the 45,098 target units, or fully upon a change in control before that date.

He also received options to buy 67,779 shares of common stock at an exercise price of $4.35 per share, expiring on March 17, 2036. All transactions are grants or awards, not open-market purchases or sales.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider KALBERMATTEN ADAM R

Role President-Chief Commercial Off

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	45,098	$0.00	--
Grant/Award	Performance Stock Unit	45,098	$0.00	--
Grant/Award	Option to buy Common Stock	67,779	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 45,098 shares (Direct); Performance Stock Unit — 45,098 shares (Direct); Option to buy Common Stock — 67,779 shares (Direct)

Footnotes (1)

1. Each unit represents a right to receive one share of common stock underlying the vested award on the applicable vesting date. The units comprising the award vest in equal increments on March 17, 2027 and each first, second and third anniversaries thereof (each, a vesting date). These units will vest based upon the achievement of certain performance conditions as of December 31, 2028. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-150% of the amount reported depending on the level of performance achieved. These units will vest at 100% of the amount reported upon a change in control of the Company prior to December 31, 2028.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KALBERMATTEN ADAM R

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President-Chief Commercial Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/17/2026		A		45,098		(2)	(2)	Common Stock	45,098	$0	45,098	D
Performance Stock Unit	(1)	03/17/2026		A		45,098		(3)	(3)	Common Stock	45,098	$0	45,098	D
Option to buy Common Stock	$4.35	03/17/2026		A		67,779		(2)	03/17/2036	Common Stock	67,779	$0	67,779	D

Explanation of Responses:

1. Each unit represents a right to receive one share of common stock underlying the vested award on the applicable vesting date.

2. The units comprising the award vest in equal increments on March 17, 2027 and each first, second and third anniversaries thereof (each, a vesting date).

3. These units will vest based upon the achievement of certain performance conditions as of December 31, 2028. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-150% of the amount reported depending on the level of performance achieved. These units will vest at 100% of the amount reported upon a change in control of the Company prior to December 31, 2028.

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KRMD report for Adam R. Kalbermatten?

KORU Medical Systems reported that President and Chief Commercial Officer Adam R. Kalbermatten received equity compensation grants, including restricted stock units, performance stock units, and stock options, all awarded on March 17, 2026 as part of his role rather than through open-market trading.

How many restricted and performance stock units did KRMD grant to Adam R. Kalbermatten?

Adam R. Kalbermatten was granted 45,098 restricted stock units and 45,098 performance stock units, each unit representing a right to receive one share of KORU Medical Systems common stock if the applicable time-based or performance-based vesting conditions are ultimately satisfied.

How do Adam R. Kalbermatten’s performance stock units at KRMD vest?

The performance stock units will vest based on achieving specified performance conditions measured as of December 31, 2028. Payout can range from 0% to 150% of the 45,098 target units, or 100% upon a change in control of the company before that date.

What are the key terms of Adam R. Kalbermatten’s KRMD stock option grant?

Adam R. Kalbermatten received options to buy 67,779 shares of KORU Medical Systems common stock at an exercise price of $4.35 per share. These options are scheduled to expire on March 17, 2036, providing a long-term equity incentive opportunity.

Are Adam R. Kalbermatten’s KRMD Form 4 transactions market buys or sells?

The reported transactions are compensation-related grants, not market buys or sells. They include awards of restricted stock units, performance stock units, and stock options, all issued at no cash cost to the insider on the grant date as part of his executive compensation package.